宣泰医药
(688247)
| 流通市值：41.53亿 | | | 总市值：41.53亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 143,878,735.73 | 407,111,314.29 | 249,100,119.81 | 209,050,861.02 |
| 交易性金融资产 | 633,461,272.6 | 339,341,275.35 | 516,443,068.49 | 534,112,246.52 |
| 应收票据及应收账款 | 62,489,667.2 | 80,003,716.62 | 83,473,147 | 82,119,143.97 |
| 其中：应收票据 | 50,000 | 50,000 | - | - |
| 应收账款 | 62,439,667.2 | 79,953,716.62 | 83,473,147 | 82,119,143.97 |
| 预付款项 | 18,262,612.24 | 15,264,322.29 | 11,120,911.33 | 9,032,548.9 |
| 其他应收款合计 | 9,676,205.55 | 3,242,682.6 | 3,707,396.45 | 3,656,761.84 |
| 存货 | 65,038,476.59 | 72,546,096.3 | 90,169,385.2 | 100,712,763.05 |
| 合同资产 | 9,944,677.21 | 6,245,350.07 | 11,036,881.41 | 11,338,686.84 |
| 其他流动资产 | 12,557,897.23 | 11,118,502.54 | 8,184,765.54 | 8,014,403.87 |
| 流动资产合计 | 955,309,544.35 | 934,873,260.06 | 973,235,675.23 | 958,037,416.01 |
| 非流动资产: | | | | |
| 长期股权投资 | 64,600,854.43 | 64,269,297.57 | 65,792,803.07 | 65,141,985.16 |
| 其他非流动金融资产 | 20,000,000 | 20,000,000 | - | - |
| 固定资产 | 304,102,132.92 | 306,277,664.62 | 294,776,272.02 | 297,882,230.19 |
| 在建工程 | 58,126,729.52 | 57,576,398.81 | 63,986,228.99 | 61,111,701.01 |
| 使用权资产 | 5,312.81 | 21,251.27 | 37,189.73 | 53,128.19 |
| 无形资产 | 13,318,083.13 | 14,976,762.4 | 16,649,558.54 | 18,264,604.24 |
| 商誉 | 16,221,129.97 | 16,221,129.97 | 18,385,750.74 | 18,385,750.74 |
| 长期待摊费用 | 374,106.24 | 460,413.79 | 552,209.68 | 680,440.08 |
| 递延所得税资产 | 18,457,295.21 | 19,011,820.87 | 18,544,190.61 | 18,760,496.93 |
| 其他非流动资产 | 3,554,770.8 | 4,411,384.07 | 4,363,384.96 | 5,095,556.36 |
| 非流动资产合计 | 498,760,415.03 | 503,226,123.37 | 483,087,588.34 | 485,375,892.9 |
| 资产总计 | 1,454,069,959.38 | 1,438,099,383.43 | 1,456,323,263.57 | 1,443,413,308.91 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 26,219,826.36 | 25,862,109.75 | 20,641,748.04 | 21,875,107.81 |
| 应付账款 | 26,219,826.36 | 25,862,109.75 | 20,641,748.04 | 21,875,107.81 |
| 合同负债 | 34,320,091.97 | 29,912,649.06 | 28,488,342.55 | 30,216,454.39 |
| 应付职工薪酬 | 6,158,611.09 | 10,684,758.92 | 9,003,326.67 | 8,833,557.22 |
| 应交税费 | 2,824,931.75 | 2,969,182.83 | 4,324,314.21 | 2,443,683.52 |
| 其他应付款合计 | 15,050,231.14 | 11,087,810.56 | 16,260,911.4 | 7,495,747.63 |
| 应付股利 | 1,761,047.97 | 1,761,047.97 | 11,225,097.28 | - |
| 一年内到期的非流动负债 | 6,593.74 | 22,550.86 | 22,271.31 | 38,187.26 |
| 其他流动负债 | 2,396,347.47 | 2,420,302.54 | 948,421.7 | 1,265,608.91 |
| 流动负债合计 | 86,976,633.52 | 82,959,364.52 | 79,689,335.88 | 72,168,346.74 |
| 非流动负债: | | | | |
| 长期应付职工薪酬 | 908,246 | 908,246 | - | - |
| 预计负债 | 1,573,016.14 | 1,573,016.14 | - | - |
| 递延收益 | 53,886,467.53 | 58,428,381.12 | 66,364,934.98 | 67,614,014.86 |
| 递延所得税负债 | 2,213,049.29 | 2,248,686.2 | 2,286,560.86 | 2,322,201.15 |
| 非流动负债合计 | 58,580,778.96 | 63,158,329.46 | 68,651,495.84 | 69,936,216.01 |
| 负债合计 | 145,557,412.48 | 146,117,693.98 | 148,340,831.72 | 142,104,562.75 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 453,340,000 | 453,340,000 | 453,340,000 | 453,340,000 |
| 资本公积 | 512,908,073.11 | 512,924,510.11 | 512,937,672 | 512,902,400.27 |
| 减:库存股 | 36,126,025.26 | 36,126,025.26 | 36,126,025.26 | 36,126,025.26 |
| 其他综合收益 | -36,904.97 | -20,861.17 | -12,932.76 | 357.33 |
| 盈余公积 | 34,182,632.61 | 34,182,632.61 | 32,202,213.54 | 32,202,213.54 |
| 未分配利润 | 344,244,771.41 | 327,681,433.16 | 345,641,504.33 | 338,989,800.28 |
| 归属于母公司股东权益合计 | 1,308,512,546.9 | 1,291,981,689.45 | 1,307,982,431.85 | 1,301,308,746.16 |
| 股东权益合计 | 1,308,512,546.9 | 1,291,981,689.45 | 1,307,982,431.85 | 1,301,308,746.16 |
| 负债和股东权益合计 | 1,454,069,959.38 | 1,438,099,383.43 | 1,456,323,263.57 | 1,443,413,308.91 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |